Table 3.
CARPREG II Risk Score. CARPREG: Cardiac Disease in Pregnancy Study; NYHA: New York Heart Association5
|
| |
|---|---|
| PREDICTOR | POINTS |
|
| |
| Prior cardiac events or arrhythmias | 3 |
|
| |
| Baseline NYHA III-IV or cyanosis* | 3 |
|
| |
| Mechanical valve | 3 |
|
| |
| Ventricular dysfunction | 2 |
|
| |
| High-risk left-sided valve disease/left ventricular outflow tract obstruction | 2 |
|
| |
| Pulmonary hypertension | 2 |
|
| |
| Coronary artery disease | 2 |
|
| |
| High-risk aortopathy | 2 |
|
| |
| No prior cardiac intervention | 1 |
|
| |
| Late pregnancy assessment | 1 |
|
| |
* NYHA risk groups include individuals with at least mild reduction in systemic ventricular systolic function (ejection fraction < 55%), high-risk valve lesions, or left ventricular outflow tract (LVOT) obstruction (such as aortic valve area < 1.5 cm2, subaortic gradient > 30 mm Hg, mitral valve area < 2 cm, or moderate to severe mitral regurgitation); those with mechanical valves; individuals with pulmonary hypertension (right ventricular systolic pressure ≥ 50 mm Hg in the absence of RVOT); those with high-risk aortopathy (including Marfan syndrome; bicuspid aortopathy with aortic dimension > 45 mm; Loeys-Dietz syndrome; vascular Ehlers-Danlos syndrome; or a history of aortic dissection or pseudoaneurysm); and individuals with coronary artery disease; defined as angiographically proven coronary obstruction or a history of myocardial infarction.